<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04936126</url>
  </required_header>
  <id_info>
    <org_study_id>T/EMF/Psych/19/49</org_study_id>
    <nct_id>NCT04936126</nct_id>
  </id_info>
  <brief_title>Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression</brief_title>
  <acronym>APQ-TRD</acronym>
  <official_title>Comparative Efficacy of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment-resistant Unipolar Depression: A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>All India Institute of Medical Sciences, Bhubaneswar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indian Council of Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>All India Institute of Medical Sciences, Bhubaneswar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study has been designed to compare the efficacy and safety of augmentation of&#xD;
      SSRIs with Amantadine vs Pramipexole vs the recommended Quetiapine augmentation in&#xD;
      Treatment-Resistant Depression (TRD) and correlate the changes in depression scores with&#xD;
      changes in the serum levels of Brain-derived neurotrophic factor (BDNF) and Nerve growth&#xD;
      factor (NGF).&#xD;
&#xD;
      The proposed study will be a prospective, randomized, single-blind, controlled clinical trial&#xD;
      in patients with TRD and will be conducted over a period of 2 years. The study cohort will&#xD;
      comprise 150 patients with unipolar depression clinically diagnosed as TRD, who are currently&#xD;
      on Sertraline treatment (dose range = 100-200 mg/day). At baseline, Hamilton Depression Scale&#xD;
      (HAM-D 21 item) will be administered to determine the severity of depressive symptoms,&#xD;
      Clinical Global Inventory (CGI) will be administered to determine the baseline severity of&#xD;
      the illness. Serum BDNF, and NGF will be estimated by ELISA using commercially available&#xD;
      Human ELISA kit. The sample will be divided into 3 equal treatment groups by block&#xD;
      randomization technique, each group comprising of 50 patients.&#xD;
&#xD;
      Group 1 will receive Amantadine 200 mg/day (in two divided doses) augmentation to the ongoing&#xD;
      Sertraline treatment. Group 2 will receive Pramipexole 0.375 mg/day (in three divided doses)&#xD;
      augmentation to the ongoing Sertraline treatment. Group 3 will serve as the control arm and&#xD;
      receive the recommended Quetiapine XR 100 mg/day augmentation to the ongoing Sertraline&#xD;
      treatment.&#xD;
&#xD;
      The study cohort will be reassessed for the changes in HAM-D scores, CGI severity scores,&#xD;
      Improvement score and Efficacy index, at 4 and 8 weeks follow up. The changes in Serum BDNF,&#xD;
      and NGF will be estimated at the end of 8 weeks, to correlate with the change in severity of&#xD;
      depressive symptoms. All the participants will be evaluated for any untoward side effects in&#xD;
      a prescribed format for the Pharmacovigilance program of India (PVPI). The patient in either&#xD;
      of the treatment arms, who are not responding to treatment or relapsing with aggravation of&#xD;
      depressive symptoms will be switched on to Venlafaxine treatment or Electro-convulsive&#xD;
      therapy (ECT) as decided by the treating team.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY OBJECTIVES:&#xD;
&#xD;
      Primary Objective&#xD;
&#xD;
      â€¢ To compare the change in the severity of symptoms of depression in terms of change in HAM-D&#xD;
      scores between the treatment groups over 8 weeks.&#xD;
&#xD;
      Secondary Objective&#xD;
&#xD;
        -  To compare the change in CGI scores between the treatment groups over 8 weeks.&#xD;
&#xD;
        -  To evaluate the change in serum BDNF, serum NGF levels between the treatment groups over&#xD;
           8 weeks.&#xD;
&#xD;
        -  To detect adverse drug reactions (if any) (prescribed format for Pharmacovigilance&#xD;
           program of India PVPI)&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      This study will be a hospital-based, prospective, randomized, single-blind, controlled&#xD;
      clinical trial in patients with unipolar depression clinically diagnosed as TRD, which will&#xD;
      be conducted over a period of 3 years.&#xD;
&#xD;
      Study population and eligibility:&#xD;
&#xD;
      The study cohort will comprise of 150 patients with the diagnosis of unipolar&#xD;
      treatment-resistant depression (TRD), attending the in-patient or out-patient department of&#xD;
      Psychiatry, All India Institute of Medical Sciences, Bhubaneswar. The patient should have&#xD;
      received adequate trials of at least two antidepressants (one of which preferably should be&#xD;
      an SSRI) at adequate dose and duration (&gt; 6 weeks), with poor clinical response while on&#xD;
      regular compliance. The patients fulfilling the criteria who are currently on Sertraline&#xD;
      treatment (dose range = 100-200 mg/day), giving written informed consent will be recruited&#xD;
      for the present study. The detailed history, relevant socio-demographic, and clinical data&#xD;
      will be collected in a structured case record form (CRF).&#xD;
&#xD;
      Study Procedure and Data collection:&#xD;
&#xD;
      Baseline assessment:&#xD;
&#xD;
      At baseline, Hamilton Depression Scale (HAM-D 21 item) will be administered to determine the&#xD;
      severity of depressive symptoms, Clinical Global Inventory (CGI) will be administered to&#xD;
      determine the baseline severity of the illness. Serum BDNF, and NGF will be estimated by&#xD;
      ELISA using commercially available Human ELISA kit.&#xD;
&#xD;
      Randomization:&#xD;
&#xD;
      The study cohort of 150 participants will be randomized into three treatment groups by block&#xD;
      randomization technique (computer-generated) with 25 blocks, each block with 6 participants.&#xD;
      The sample will be divided into 3 equal treatment groups, each group comprising of 50&#xD;
      patients.&#xD;
&#xD;
      Treatment Allocation:&#xD;
&#xD;
      Group 1 will receive Amantadine 200 mg/day (in two divided doses) augmentation to the ongoing&#xD;
      Sertraline treatment. Group 2 will receive Pramipexole 0.375 mg/day (in three divided doses)&#xD;
      augmentation to the ongoing Sertraline treatment. Group 3 will serve as the control arm and&#xD;
      receive the recommended Quetiapine XR 100 mg/day augmentation to the ongoing Sertraline&#xD;
      treatment.&#xD;
&#xD;
      Follow up assessment:&#xD;
&#xD;
      The study cohort will be reassessed for the changes in HAM-D scores, CGI severity scores,&#xD;
      Improvement score, and Efficacy index, at 4 and 8 weeks follow up. The changes in Serum BDNF&#xD;
      and NGF will be estimated at the end of 8 weeks, to correlate with the change in the severity&#xD;
      of depressive symptoms.&#xD;
&#xD;
      Rescue Medication:&#xD;
&#xD;
      The patient in either of the treatment arms, who are not responding to treatment or relapsing&#xD;
      with aggravation of depressive symptoms will be switched on to Venlafaxine treatment or ECT&#xD;
      as decided by the treating team.&#xD;
&#xD;
      Safety evaluation:&#xD;
&#xD;
      All the participants will be evaluated for any untoward side effects like insomnia,&#xD;
      restlessness, and agitation, etc. which will be documented and informed to the institutional&#xD;
      ethics committee.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 7, 2021</start_date>
  <completion_date type="Anticipated">September 7, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 7, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, parallel-arm, randomized, single-blind, controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The outcome assessor will remain blind to the treatment allocation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Scale scores</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in Hamilton Depression Scale scores 8-16 suggest mild depression, 17-23 moderate depression and scores over 24 are indicative of severe depression Higher scores indicating higher severity of depression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression scores</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in Clinical Global Impression scores CGI-S severity scores range from 1-7, with higher scores indicating greater severity of illness CGI-I Improvement score range from 1-7, with lower scores indicating improvement and higher scores indicating worsening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Brain Derived Neurotrophic Factor</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in Serum Brain Derived Neurotrophic Factor levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Nerve Growth Factor</measure>
    <time_frame>8 week</time_frame>
    <description>Change in Serum Nerve Growth Factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medications</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of patients in the Rescue medication group</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <arm_group>
    <arm_group_label>Quetiapine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Quetiapine XR 100 mg/day augmentation to the ongoing Sertraline treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amantadine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amantadine 200 mg/day (in two divided doses) augmentation to the ongoing Sertraline treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pramipexole group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pramipexole 0.375 mg/day (in three divided doses) augmentation to the ongoing Sertraline treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <description>Quetiapine XR 100 mg/day augmentation to the ongoing Sertraline treatment for the study period</description>
    <arm_group_label>Quetiapine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amantadine</intervention_name>
    <description>Amantadine 200 mg/day (in two divided doses) augmentation to the ongoing Sertraline treatment for the study period</description>
    <arm_group_label>Amantadine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramipexole</intervention_name>
    <description>Pramipexole 0.375 mg/day (in three divided doses) augmentation to the ongoing Sertraline treatment for the study period</description>
    <arm_group_label>Pramipexole group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with unipolar depression clinically diagnosed as TRD, who are currently on&#xD;
             Sertraline treatment (dose range = 100-200 mg/day)&#xD;
&#xD;
          2. Patients aged 18-60 years of either sex&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with Bipolar affective disorder&#xD;
&#xD;
          2. Patient with TRD on antidepressants other than Sertraline&#xD;
&#xD;
          3. History of psychoactive substance abuse or dependence&#xD;
&#xD;
          4. Co-morbid psychiatric, major medical, or neurological disorders&#xD;
&#xD;
          5. History of organicity or significant head injury&#xD;
&#xD;
          6. Pregnant and lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debadatta Mohapatra, MD</last_name>
    <role>Study Chair</role>
    <affiliation>All India Institute of Medical Sciences, Bhubaneswar</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Biswa R Mishra, MD, DPM</last_name>
    <phone>9438884220</phone>
    <email>brm1678@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rituparna Maiti, MD</last_name>
    <phone>9438884191</phone>
    <email>rituparnamaiti@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>Bhubaneswar</city>
        <state>Orissa</state>
        <zip>751019</zip>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>Biswa R Mishra, MD, DPM</last_name>
      <phone>9438884220</phone>
      <email>brm1678@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Rituparna Maiti, MD</last_name>
      <phone>9438884191</phone>
      <email>rituparnamaiti@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Debadatta Mohapatra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <results_reference>
    <citation>GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1545-1602. doi: 10.1016/S0140-6736(16)31678-6. Erratum in: Lancet. 2017 Jan 7;389(10064):e1.</citation>
    <PMID>27733282</PMID>
  </results_reference>
  <results_reference>
    <citation>Kennedy SH, Giacobbe P. Treatment resistant depression--advances in somatic therapies. Ann Clin Psychiatry. 2007 Oct-Dec;19(4):279-87. Review.</citation>
    <PMID>18058285</PMID>
  </results_reference>
  <results_reference>
    <citation>Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996 Jun;19(2):179-200. Review.</citation>
    <PMID>8827185</PMID>
  </results_reference>
  <results_reference>
    <citation>Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, Racagni G, Zohar J, Mendlewicz J. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999 Jan;9(1-2):83-91. Review.</citation>
    <PMID>10082232</PMID>
  </results_reference>
  <results_reference>
    <citation>Dold M, Kasper S. Evidence-based pharmacotherapy of treatment-resistant unipolar depression. Int J Psychiatry Clin Pract. 2017 Mar;21(1):13-23. doi: 10.1080/13651501.2016.1248852. Epub 2016 Nov 16. Review.</citation>
    <PMID>27848269</PMID>
  </results_reference>
  <results_reference>
    <citation>Fleurence R, Williamson R, Jing Y, Kim E, Tran QV, Pikalov AS, Thase ME. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol Bull. 2009;42(3):57-90. Review.</citation>
    <PMID>19752841</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>June 26, 2021</last_update_submitted>
  <last_update_submitted_qc>June 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>All India Institute of Medical Sciences, Bhubaneswar</investigator_affiliation>
    <investigator_full_name>BISWA RANJAN MISHRA</investigator_full_name>
    <investigator_title>Additional Professor, Department of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Treatment Resistant Depression</keyword>
  <keyword>Augmentation</keyword>
  <keyword>Amantadine</keyword>
  <keyword>Pramipexole</keyword>
  <keyword>BDNF</keyword>
  <keyword>NGF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amantadine</mesh_term>
    <mesh_term>Pramipexole</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

